1. Overview
Factor V is an essential protein involved in the blood coagulation process. The Factor V Leiden mutation is a genetic alteration in the F5 gene that leads to an increased risk of abnormal blood clot formation, most commonly affecting the veins of the legs and lungs. Despite this association, the majority of individuals carrying the Factor V Leiden mutation never develop abnormal clots.
The mutation is described as having semi-dominant inheritance with incomplete penetrance. Heterozygous individuals carry a relatively lower risk of thrombotic events, whereas homozygous individuals have a significantly higher likelihood of developing thrombosis. This mutation primarily predisposes individuals to venous thromboembolism rather than arterial thrombosis.
2. Symptoms
Factor V Leiden mutation itself does not cause direct symptoms. Clinical manifestations occur only when thrombosis develops. These may include symptoms related to venous thromboembolism, such as swelling, pain, or redness in the affected limb, and complications associated with pulmonary embolism when clots migrate to the lungs. Thrombotic events may occur at an early age or at unusual anatomical sites in certain individuals.
3. Causes
The underlying cause of Factor V Leiden is a specific genetic mutation in the F5 gene, commonly referred to as the R506Q mutation. This genetic change alters the normal regulation of Factor V, leading to resistance to natural anticoagulant mechanisms and a tendency toward excessive clot formation. The mutation is inherited, and the risk of disease manifestation depends on whether one or both parents carry the altered gene.
4. Risk Factors
Several factors increase the risk of thrombosis in individuals with the Factor V Leiden mutation. These include a personal or family history of venous thromboembolism, especially when events occur before 50 years of age. Homozygous individuals have a markedly higher risk compared to heterozygous carriers.
Additional risk is observed when the mutation is combined with other inherited thrombophilias or acquired risk factors. Thrombosis may also occur at atypical sites such as the ovarian, portal, or renal veins. Pregnancy, the postpartum period, and a positive family history of early-onset thrombosis further elevate the risk. Although common among Caucasian populations, many carriers remain asymptomatic throughout life.
5. Prevention and Clinical Management
Prevention and management focus on early identification, risk assessment, and appropriate clinical guidance rather than routine treatment for all carriers. Testing for Factor V Leiden mutation is indicated in cases of unexplained or recurrent venous thromboembolism, early-onset thrombosis, family history of thrombotic disorders, and thrombosis at unusual sites.
Proper patient counseling and informed consent are emphasized before testing, as it is a genetic investigation. Diagnostic evaluation is performed using molecular techniques such as polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP), real-time PCR, DNA sequencing, and other advanced genetic methods.
Sample collection typically involves whole blood in EDTA or citrate tubes, or buccal swabs for DNA analysis, with strict guidelines for processing, storage, and transportation to ensure result accuracy.
A negative test result indicates the absence of the Factor V Leiden mutation, while a positive result aids in explaining unprovoked or recurrent thrombotic events, assessing hereditary risk, guiding anticoagulation therapy decisions, and screening family members.
The clinical utility of testing lies in risk stratification, pregnancy-related thrombosis evaluation, and long-term management planning. Limitations of testing include the inability to detect rare F5 gene mutations other than the commonly targeted Leiden mutation.
